Literature DB >> 21374060

Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case--control study.

Hong-Xiang Gu1, Ya-Li Zhang, Fa-Chao Zhi, Bo Jiang, Ying Huang.   

Abstract

PURPOSE: The diagnosis of irritable bowel syndrome is symptom based, and colonoscopy is the most direct way to rule out organic colonic diseases. It is controversial on the necessity of colonoscopy for patients with suspected irritable bowel syndrome and lacking alarm features. This study was designed to verify the organic lesions and discuss the value of colonoscopy in this type of patients.
METHODS: Colonoscopy of 3,332 patients with suspected irritable bowel syndrome and lacking warning signs from 2000 to 2009 were reviewed. One thousand five hundred eighty-eight patients under 50 years of age who underwent colonoscopy screening for health care in the same period were used as controls. The prevalence of different colonic organic lesions was compared between two groups.
RESULTS: Organic colonic lesions were found in 30.3% of the patients with suspected irritable bowel syndrome (1,010/3,332) and 39.0% of the controls (619/1,588). Compared with controls, patients with suspected irritable bowel syndrome had higher prevalence of noninflammatory bowel disease and noninfectious colitis and terminal ileitis, however, had lower prevalence of diverticular disease, adenomatous polyps, and non-adenomatous polyps (all P < 0.001).
CONCLUSIONS: The diagnostic sensitivity of symptom criteria on irritable bowel syndrome without colonoscopy is not more than 69.7% in patients with suspected irritable bowel syndrome lacking warning signs. Though the method of colonoscopy is hard to screen tumor in this type of patients, it is beneficial to uncover some other relevant organic lesions such as terminal ileitis. Colonoscopy should not be refused to suspected irritable bowel syndrome patients without warning signs.

Entities:  

Mesh:

Year:  2011        PMID: 21374060     DOI: 10.1007/s00384-011-1163-2

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  26 in total

Review 1.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

2.  Activation of the mucosal immune system in irritable bowel syndrome.

Authors:  Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

3.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

4.  A simple score for the identification of patients at high risk of organic diseases of the colon in the family doctor consulting room. The Local IBS Study Group.

Authors:  S Bellentani; P Baldoni; S Petrella; C Tata; C Armocida; P Marchegiano; G Saccoccio; F Manenti
Journal:  Fam Pract       Date:  1990-12       Impact factor: 2.267

Review 5.  Diagnostic approach to suspected irritable bowel syndrome.

Authors:  J G Hatlebakk; M V Hatlebakk
Journal:  Best Pract Res Clin Gastroenterol       Date:  2004-08       Impact factor: 3.043

Review 6.  New developments in the diagnosis and treatment of irritable bowel syndrome.

Authors:  George F Longstreth; Douglas A Drossman
Journal:  Curr Gastroenterol Rep       Date:  2002-10

Review 7.  Efficient diagnosis of suspected functional bowel disorders.

Authors:  Jenny Gunnarsson; Magnus Simrén
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-09

8.  Terminal ileal mucosal mast cells in irritable bowel syndrome.

Authors:  A P Weston; W L Biddle; P S Bhatia; P B Miner
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

9.  [A population-based epidemiologic study of irritable bowel syndrome in Guangdong province].

Authors:  Li-shou Xiong; Min-hu Chen; Hui-xin Chen; An-gao Xu; Wei-an Wang; Pin-jin Hu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2004-02-17

10.  Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study.

Authors:  Hye-Kyung Jung; Rok Seon Choung; G Richard Locke; Cathy D Schleck; Alan R Zinsmeister; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2009-10-27       Impact factor: 10.864

View more
  7 in total

1.  The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study.

Authors:  Masaaki Yamamoto; Hidenori Fukuoka; Genzo Iguchi; Ryusaku Matsumoto; Michiko Takahashi; Hitoshi Nishizawa; Kentaro Suda; Hironori Bando; Yutaka Takahashi
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

2.  Diagnostic yield of endoscopy in irritable bowel syndrome: A nationwide prevalence study 1987-2016.

Authors:  Kyle Staller; Ola Olén; Jonas Söderling; Bjorn Roelstraete; Hans Törnblom; Hamed Khalili; Mingyang Song; Jonas F Ludvigsson
Journal:  Eur J Intern Med       Date:  2021-08-20       Impact factor: 4.487

3.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS).

Authors:  Paul Moayyedi; Christopher N Andrews; Glenda MacQueen; Christina Korownyk; Megan Marsiglio; Lesley Graff; Brent Kvern; Adriana Lazarescu; Louis Liu; William G Paterson; Sacha Sidani; Stephen Vanner
Journal:  J Can Assoc Gastroenterol       Date:  2019-01-17

4.  Evidence-based clinical practice guidelines for irritable bowel syndrome 2020.

Authors:  Shin Fukudo; Toshikatsu Okumura; Masahiko Inamori; Yusuke Okuyama; Motoyori Kanazawa; Takeshi Kamiya; Ken Sato; Akiko Shiotani; Yuji Naito; Yoshiko Fujikawa; Ryota Hokari; Tastuhiro Masaoka; Kazuma Fujimoto; Hiroshi Kaneko; Akira Torii; Kei Matsueda; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-02-04       Impact factor: 7.527

5.  Predictive value of alarm symptoms in Rome IV irritable bowel syndrome: A multicenter cross-sectional study.

Authors:  Qian Yang; Zhong-Cao Wei; Na Liu; Yang-Lin Pan; Xiao-Sa Jiang; Xin-Xing Tantai; Qi Yang; Juan Yang; Jing-Jie Wang; Lei Shang; Qiang Lin; Cai-Lan Xiao; Jin-Hai Wang
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

Review 6.  The epidemiology of irritable bowel syndrome.

Authors:  Caroline Canavan; Joe West; Timothy Card
Journal:  Clin Epidemiol       Date:  2014-02-04       Impact factor: 4.790

7.  Prevalence of Organic Colonic Lesions by Colonoscopy in Patients Fulfilling ROME IV Criteria of Irritable Bowel Syndrome.

Authors:  Mukesh Sharma Paudel; Amrendra Kumar Mandal; Barun Shrestha; Nandu Silwal Poudyal; Sudhamshu Kc; Sitaram Chaudhary; Ramila Shrestha; Khushboo Goel
Journal:  JNMA J Nepal Med Assoc       Date:  2018 Jan-Feb       Impact factor: 0.406

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.